1.0400 0.00 (0.00%)
After hours: 5:53PM EDT
|Bid||1.0400 x 21500|
|Ask||1.1200 x 34100|
|Day's Range||1.0300 - 1.1000|
|52 Week Range||0.9400 - 3.0400|
|Beta (3Y Monthly)||2.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
WESTLAKE VILLAGE, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that it has partnered with GoodRx to help raise awareness on ways patients can save money on their mealtime insulin.
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility. This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization.
If you want to know who really controls MannKind Corporation (NASDAQ:MNKD), then you'll have to look at the makeup of...
New data from three different studies of Afrezza was announced at the American Diabetes Association’s 79th Scientific Sessions (June 7 – 11) in San Francisco. This includes safety and PK data from MannKind’s (MNKD) ongoing pediatric study. This pediatric data, which comes from the first of three age-based patient cohorts is particularly insightful as it provides one of the initial meaningful glimpses of utility of Afrezza in younger populations.
WESTLAKE VILLAGE, Calif., June 12, 2019 -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.
MannKind Corporation (MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11, in San Francisco, California. MannKind will present a poster with initial information from its ongoing study of Safety and Pharmacokinetics of Technosphere Insulin (Afrezza) in Pediatric Patients ¹ on Monday, June 10. This study is the first step in preparation for a phase 3 safety and efficacy study.
Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, June 03, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) and BIOMM SA (BIOM3.SA) today announced that Afrezza® (insulin human) Inhalation Powder, an ultra rapid-acting mealtime insulin to improve glycemic control in adult patients with diabetes mellitus, has been registered by the Brazilian Health Regulatory Agency (ANVISA).
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
MannKind Corporation (MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. for the commercialization of Afrezza® (insulin human) Inhalation Powder in Australia. "We are excited to partner with AMSL Diabetes to accelerate patients’ access to Afrezza in Australia," said Michael Castagna, Chief Executive Officer of MannKind Corporation.
MannKind (MNKD) reported financial results for their first quarter ending March 31st and provided a business update. As it relates to the financials, total revenue was $17.4M, which included $5.1M in product sales and $12.4M in collaboration revenue.
The Westlake Village, California-based company said it had a loss of 8 cents per share. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
1Q 2019 Total Revenues of $17.4 million 1Q 2019 Afrezza Net Revenue was $5.1 million; +49% vs. 1Q 2018 1Q 2019 Collaborations and Services Revenue was $12.4 million 1Q 2019 net.
United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
WESTLAKE VILLAGE, Calif., April 30, 2019 -- MannKind Corporation (Nasdaq:MNKD) will release its 2019 first quarter financial results on Tuesday, May 7, 2019 and its management.
WESTLAKE VILLAGE, Calif., April 25, 2019 -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be.
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company. The presentation will be webcast live. To access the webcast, please visit www.hcwevents.com. Interested parties can also access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.
MannKind Corporation (MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones. MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect upside potential of 75.00% for MannKind (MNKD) based on the company’s closing price on March
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Financial performance In the fourth quarter, MannKind Corporation (MNKD) reported revenue of $16.03 million, a YoY (year-over-year) rise of 253.91%. According
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Growth trendsIn its fourth-quarter earnings investor presentation, MannKind Corporation (MNKD) announced that Afrezza had seen fiscal 2018 net sales of $17.3
MannKind or Akebia: Which Is a Better Biotech Pick This Month?Share price movementsOn March 12, MannKind Corporation (MNKD) closed at $2.09, 8.29% higher than its previous closing price, 122.34% higher than its 52-week low of $0.94, and 31.25% lower